Literature DB >> 33575657

T cell phenotypes in COVID-19 - a living review.

Stephanie J Hanna1, Amy S Codd1, Ester Gea-Mallorqui2, D Oliver Scourfield1, Felix C Richter3, Kristin Ladell1, Mariana Borsa3, Ewoud B Compeer3, Owen R Moon1, Sarah A E Galloway1, Sandra Dimonte1, Lorenzo Capitani1, Freya R Shepherd1, Joseph D Wilson4, Lion F K Uhl3, Awen M Gallimore1, Anita Milicic5.   

Abstract

COVID-19 is characterized by profound lymphopenia in the peripheral blood, and the remaining T cells display altered phenotypes, characterized by a spectrum of activation and exhaustion. However, antigen-specific T cell responses are emerging as a crucial mechanism for both clearance of the virus and as the most likely route to long-lasting immune memory that would protect against re-infection. Therefore, T cell responses are also of considerable interest in vaccine development. Furthermore, persistent alterations in T cell subset composition and function post-infection have important implications for patients' long-term immune function. In this review, we examine T cell phenotypes, including those of innate T cells, in both peripheral blood and lungs, and consider how key markers of activation and exhaustion correlate with, and may be able to predict, disease severity. We focus on SARS-CoV-2-specific T cells to elucidate markers that may indicate formation of antigen-specific T cell memory. We also examine peripheral T cell phenotypes in recovery and the likelihood of long-lasting immune disruption. Finally, we discuss T cell phenotypes in the lung as important drivers of both virus clearance and tissue damage. As our knowledge of the adaptive immune response to COVID-19 rapidly evolves, it has become clear that while some areas of the T cell response have been investigated in some detail, others, such as the T cell response in children remain largely unexplored. Therefore, this review will also highlight areas where T cell phenotypes require urgent characterisation.
© The Author(s) 2020. Published by Oxford University Press.

Entities:  

Keywords:  COVID-19; T cells; antigen-specific; lung; peripheral blood; phenotypes

Year:  2020        PMID: 33575657      PMCID: PMC7798577          DOI: 10.1093/oxfimm/iqaa007

Source DB:  PubMed          Journal:  Oxf Open Immunol        ISSN: 2633-6960


  56 in total

1.  Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19.

Authors:  Jennifer A Juno; Hyon-Xhi Tan; Stephen J Kent; Adam K Wheatley; Wen Shi Lee; Arnold Reynaldi; Hannah G Kelly; Kathleen Wragg; Robyn Esterbauer; Helen E Kent; C Jane Batten; Francesca L Mordant; Nicholas A Gherardin; Phillip Pymm; Melanie H Dietrich; Nichollas E Scott; Wai-Hong Tham; Dale I Godfrey; Kanta Subbarao; Miles P Davenport
Journal:  Nat Med       Date:  2020-07-13       Impact factor: 53.440

2.  SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.

Authors:  Nina Le Bert; Anthony T Tan; Kamini Kunasegaran; Christine Y L Tham; Morteza Hafezi; Adeline Chia; Melissa Hui Yen Chng; Meiyin Lin; Nicole Tan; Martin Linster; Wan Ni Chia; Mark I-Cheng Chen; Lin-Fa Wang; Eng Eong Ooi; Shirin Kalimuddin; Paul Anantharajah Tambyah; Jenny Guek-Hong Low; Yee-Joo Tan; Antonio Bertoletti
Journal:  Nature       Date:  2020-07-15       Impact factor: 49.962

3.  COVID-19 in children and altered inflammatory responses.

Authors:  Eleanor J Molloy; Cynthia F Bearer
Journal:  Pediatr Res       Date:  2020-04-03       Impact factor: 3.756

Review 4.  SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview

Authors:  Ali A Rabaan; Shamsah H Al-Ahmed; Shafiul Haque; Ranjit Sah; Ruchi Tiwari; Yashpal Singh Malik; Kuldeep Dhama; M Iqbal Yatoo; D Katterine Bonilla-Aldana; Alfonso J Rodriguez-Morales
Journal:  Infez Med       Date:  2020 Ahead Of Print Jun 1

Review 5.  T cell-mediated immune response to respiratory coronaviruses.

Authors:  Rudragouda Channappanavar; Jincun Zhao; Stanley Perlman
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

Review 6.  Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Infection, Immunological Response, and Vaccine Development.

Authors:  Ayman Mubarak; Wael Alturaiki; Maged Gomaa Hemida
Journal:  J Immunol Res       Date:  2019-04-07       Impact factor: 4.818

7.  Early Phases of COVID-19 Are Characterized by a Reduction in Lymphocyte Populations and the Presence of Atypical Monocytes.

Authors:  Andrea Lombardi; Elena Trombetta; Alessandra Cattaneo; Valeria Castelli; Emanuele Palomba; Mario Tirone; Davide Mangioni; Giuseppe Lamorte; Maria Manunta; Daniele Prati; Ferruccio Ceriotti; Roberta Gualtierotti; Giorgio Costantino; Stefano Aliberti; Vittorio Scaravilli; Giacomo Grasselli; Andrea Gori; Laura Porretti; Alessandra Bandera
Journal:  Front Immunol       Date:  2020-12-09       Impact factor: 7.561

8.  Single-cell analysis reveals bronchoalveolar epithelial dysfunction in COVID-19 patients.

Authors:  Jiangping He; Shuijiang Cai; Huijian Feng; Baomei Cai; Lihui Lin; Yuanbang Mai; Yinqiang Fan; Airu Zhu; Huang Huang; Junjie Shi; Dingxin Li; Yuanjie Wei; Yueping Li; Yingying Zhao; Yuejun Pan; He Liu; Xiaoneng Mo; Xi He; Shangtao Cao; FengYu Hu; Jincun Zhao; Jie Wang; Nanshan Zhong; Xinwen Chen; Xilong Deng; Jiekai Chen
Journal:  Protein Cell       Date:  2020-09       Impact factor: 14.870

9.  Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm.

Authors:  Chuang Guo; Bin Li; Huan Ma; Xiaofang Wang; Pengfei Cai; Qiaoni Yu; Lin Zhu; Liying Jin; Chen Jiang; Jingwen Fang; Qian Liu; Dandan Zong; Wen Zhang; Yichen Lu; Kun Li; Xuyuan Gao; Binqing Fu; Lianxin Liu; Xiaoling Ma; Jianping Weng; Haiming Wei; Tengchuan Jin; Jun Lin; Kun Qu
Journal:  Nat Commun       Date:  2020-08-06       Impact factor: 14.919

10.  Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans.

Authors:  Alessandro Sette; Daniela Weiskopf; Jose Mateus; Alba Grifoni; Alison Tarke; John Sidney; Sydney I Ramirez; Jennifer M Dan; Zoe C Burger; Stephen A Rawlings; Davey M Smith; Elizabeth Phillips; Simon Mallal; Marshall Lammers; Paul Rubiro; Lorenzo Quiambao; Aaron Sutherland; Esther Dawen Yu; Ricardo da Silva Antunes; Jason Greenbaum; April Frazier; Alena J Markmann; Lakshmanane Premkumar; Aravinda de Silva; Bjoern Peters; Shane Crotty
Journal:  Science       Date:  2020-08-04       Impact factor: 47.728

View more
  5 in total

Review 1.  Neutrophilia, lymphopenia and myeloid dysfunction: a living review of the quantitative changes to innate and adaptive immune cells which define COVID-19 pathology.

Authors:  Amy S Codd; Stephanie J Hanna; Ewoud B Compeer; Felix C Richter; Eleanor J Pring; Ester Gea-Mallorquí; Mariana Borsa; Owen R Moon; D Oliver Scourfield; Awen M Gallimore; Anita Milicic
Journal:  Oxf Open Immunol       Date:  2021-07-15

2.  Characteristic Immune Dynamics in COVID-19 Patients with Cardiac Dysfunction.

Authors:  Filipe André Gonzalez; Miguel Ângelo-Dias; Catarina Martins; Rui Gomes; Jacobo Bacariza; Antero Fernandes; Luís Miguel Borrego
Journal:  J Clin Med       Date:  2022-03-28       Impact factor: 4.241

3.  Characterization of memory T cell subsets and common γ-chain cytokines in convalescent COVID-19 individuals.

Authors:  Anuradha Rajamanickam; Nathella Pavan Kumar; Arul Nancy Pandiaraj; Nandhini Selvaraj; Saravanan Munisankar; Rachel Mariam Renji; Vijayalakshmi Venkataramani; Manoj Murhekar; Jeromie Wesley Vivian Thangaraj; Santhosh Kumar Muthusamy; Girish Kumar Chethrapilly Purushothaman; Tarun Bhatnagar; Manickam Ponnaiah; Sabarinathan Ramasamy; Saravanakumar Velusamy; Subash Babu
Journal:  J Leukoc Biol       Date:  2022-03-08       Impact factor: 6.011

4.  Quantitative B and T cell abnormalities in four patients presenting with mucormycosis and prior asymptomatic COVID-19 infection.

Authors:  Charuta Mandke; Rohit Divekar; Vandana Pradhan; Shitij Arora
Journal:  BMJ Case Rep       Date:  2022-08-09

Review 5.  Local immune recognition of trophoblast in early human pregnancy: controversies and questions.

Authors:  Ashley Moffett; Norman Shreeve
Journal:  Nat Rev Immunol       Date:  2022-10-03       Impact factor: 108.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.